Alliance Pharma exec offloads 300,000 shares
20th Jan 2014 15:49
Speciality drugs firm Alliance Pharma announced Monday that Executive Director Anthony Booley's share in the company was reduced by 300,000 shares after his wife Lynette sold a portion of her stake. Booley, who joined the company in 1998, and his wife earned £100,500 from the sale after disposing
Read moreAlliance Pharma hits annual target and acquires Bayer product - UPDATE
14th Jan 2014 10:42
Better sales from its dermatology and post-abdominal surgery treatment products helped AIM drug company Alliance Pharma hit profit expectations for 2013. In a statement before the AIM-listed company enters its close period, Alliance said annual turnover was expected to hit £45.5m, up marginally fr
Read moreAlliance Pharma gets product mix right for first half profits
11th Sep 2013 12:02
Thanks to lower costs and slow and steady sales growth, drug investor Alliance Pharma made a strong start to the year. With sales up 4% to £22.8m in line with expectations, profits before tax 29% higher at £6.8m were ahead of analyst forecasts thanks to a product mix producing lower costs. Chairma
Read moreWednesday broker round-up UPDATE
19th Jun 2013 08:27
Aggreko: UBS cuts target price from 1975p to 1850p downgrading from buy to neutral. JP Morgan revises target price from 1870p to 1800p and retains a neutral rating. Alliance Pharma: Investec shifts target price from 35.20p to 35.80p, while downgrading from add to hold. Associated British Food: UBS
Read moreFriday tips round-up: Severn Trent, Johnson Matthey, Alliance Pharma
7th Jun 2013 07:00
Severn Trent is one of a dwindling group of remaining publicly listed water companies. For The Times´s Tempus the bidding for the water firm is not yet over. While the newspaper column does not think that its suitors will pay the 23 pounds which some institutional investors expect, it does expect a
Read moreThursday broker round-up UPDATE
6th Jun 2013 07:37
Aggreko: Goldman Sachs cuts target price from 2425p to 2125p, while retaining its buy recommendation. Alliance Pharma: FinnCap shifts target price from 35p to 38.50p and stays with its hold recommendation. APR Energy: Goldman Sachs reduces target price from 990p to 945p keeping a buy recommendatio
Read moreHargreaves Lansdown Marketing Director reduces stake by 200,000 shares
26th Oct 2012 16:27
In a deal announced after Thursday's close, Ian Hunter, the Investment Marketing Director of financial services provider Hargreaves Lansdown, has pocketed £1.51m after reducing his stake in the company by 200,000 shares. Hunter, who has held a position of the board since 2009, traded in the shares
Read moreMonday broker round-up - UPDATE
22nd Oct 2012 08:19
888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl
Read moreSmall caps round-up: Angel Biotech, Alliance Pharma, Fastjet
19th Oct 2012 14:46
Angel Biotech has seen a continuation of the 'very difficult' market conditions since mid-September, with funding constraints of clients forcing delays and changed priorities with a number of potential customers. However, the group is currently seeing an upturn in the volume of enquiries and bids, e
Read moreFriday broker round-up - UPDATE
19th Oct 2012 09:00
Aggreko: Jefferies keeps buy rating and 2,800p target; Seymour Pierce keeps buy rating and 2,500p target; Panmure Gordon cuts target from 2,228p to 2,159p, hold rating unchanged. Alliance Pharma: umps upgrades to buy, target lifted from 32p to 37p. Avacta: Panmure Gordon keeps buy rating and 1.75p
Read moreAlliance Pharma sales fall 10 per cent
12th Sep 2012 13:00
Alliance Pharma, a specialist pharmaceutical firm, reported a decline in half year pre-tax profit after revenue fell on the back of a 10% drop in sales. Sales for the six month period totalled £22.0m, down from £24.4m during the same period in 2011, dragging half year profit down from £7.0m to £5.3
Read moreSmall caps round-up: Gresham Computing, Alliance Pharma, Young and Co's...
10th Jul 2012 08:55
Gresham Computing has unveiled Australia and New Zealand Banking Group as its partner in a previously announced significant contract win. Under the deal Gresham will for a third time partner the bank, providing cash and information management solutions for corporate clients in an effort to increase
Read moreWednesday broker round-up
27th Jun 2012 09:20
Alliance Pharma: Investec downgrades from buy to hold, target slashed from 34p to 25p. APR Energy: Credit Suisse keeps outperform rating and 1,300p target. Aviva: Jefferies downgrades from buy to hold, target cut from 386p to 281p. Avanti Comms: Jefferies retains buy rating and 600p target. Brit
Read moreAlliance Pharma shares fall sharply, in part due to macro concerns
16th Jan 2012 14:50
Speciality pharmaceutical company Alliance Pharma has this morning announced its pre-close trading update for the year ended on the 31st of December of 2011. The Board expects to report turnover for 2011 of around £46m and for pre-tax profits to be in line with market expectations. Furthermore,
Read moreAlliance Pharma hikes dividend
7th Sep 2011 08:14
Pharmaceutical company, Alliance Pharma, has hiked its interim dividend after reporting a rise in profits for the first half of the year. Alliance said pre-tax profits came in at £7m, which were up from £6m the previous year and equated to earnings per share of 2.38p. However, after stripping out
Read more